243 related articles for article (PubMed ID: 29068253)
1. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Furue M; Kadono T; Tsuji G; Nakahara T
Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253
[TBL] [Abstract][Full Text] [Related]
2. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
[TBL] [Abstract][Full Text] [Related]
3. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Andoh T; Yoshida T; Kuraishi Y
Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
Ohba F; Nomoto M; Hojo S; Akama H
J Dermatolog Treat; 2016; 27(3):241-6. PubMed ID: 26581111
[TBL] [Abstract][Full Text] [Related]
5. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
6. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S;
J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H
J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
Kitahara Y; Hojo S; Nomoto M; Onozuka D; Furue M; Hagihara A
J Dermatolog Treat; 2019 Aug; 30(5):466-470. PubMed ID: 30265585
[No Abstract] [Full Text] [Related]
10. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
Wakita H; Ohkuro M; Ishii N; Hishinuma I; Shirato M
Exp Dermatol; 2015 Mar; 24(3):215-6. PubMed ID: 25431172
[TBL] [Abstract][Full Text] [Related]
11. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
Ishii N; Wakita H; Shirato M
J Dermatol Sci; 2014 Dec; 76(3):263-4. PubMed ID: 25455141
[No Abstract] [Full Text] [Related]
12. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
[TBL] [Abstract][Full Text] [Related]
13. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
[TBL] [Abstract][Full Text] [Related]
14. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Soeberdt M; Kilic A; Abels C
Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
[TBL] [Abstract][Full Text] [Related]
15. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
[TBL] [Abstract][Full Text] [Related]
16. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
[TBL] [Abstract][Full Text] [Related]
17. An overview of drug discovery efforts for eczema: why is this itch so difficult to scratch?
Hon KL; Loo S; Leung AKC; Li JTS; Lee VWY
Expert Opin Drug Discov; 2020 Apr; 15(4):487-498. PubMed ID: 32050818
[No Abstract] [Full Text] [Related]
18. Phosphodiesterase 4 inhibitors.
Zebda R; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
[TBL] [Abstract][Full Text] [Related]
19. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
[TBL] [Abstract][Full Text] [Related]
20. Atopic dermatitis: emerging therapies.
Simpson E; Udkoff J; Borok J; Tom W; Beck L; Eichenfield LF
Semin Cutan Med Surg; 2017 Sep; 36(3):124-130. PubMed ID: 28895959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
